Study #2024-1605
Optimized cord blood transplantation for the treatment of patients with high-risk hematologic malignancies who have relapsed after first allogeneic stem cell transplantation
MD Anderson Study Status
Enrolling
Treatment Agent
Drugs Cyclophosphamide, Fludarabine, Thiotepa, Tacrolimus, Mycophenolate mofetil
Description
The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hematologic Malignancies
Study phase:
Phase II
Physician name:
Warren Fingrut
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-844-829-9300
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.